To hear about similar clinical trials, please enter your email below
Trial Title:
A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma
NCT ID:
NCT05997147
Condition:
Predictive Cancer Model
Pancreas Cancer
Conditions: Official terms:
Adenocarcinoma
Pancreatic Neoplasms
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Summary:
Importance: Lymphovascular invasion (LVI) is a poor prognosis pathologic feature in
pancreatic ductal adenocarcinoma (PDAC) patients. Neoadjuvant therapy may bring survival
benefits to these patients.
Objective: To construct a preoperative model which could predict LVI in PDAC patients and
further validate it in other cohorts.
Design, Setting, and Participants: Patients from 3 three tertiary hospitals were included
in this study. Univariate and multivariate Logistic regression analyses were conducted to
define independent prediction factors of LVI. A nomogram was constructed based on the
result of multivariate analysis.The predictive value of the model was assessed using
receiver operating characteristic (ROC) curves and the maximum Youden index of the ROC
curve was defined as the cut-off point. The calibration plot was utilized to assess the
concordance of the model. The decision curve analyses (DCA) were applied to estimate the
clinical benefit of using this model to predict LVI.
Criteria for eligibility:
Study pop:
Patients who were pathologically diagnosed as PDAC and received curative surgery.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients who were pathologically diagnosed as PDAC and received curative surgery.
Exclusion Criteria:
- Patients with distant metastasis; Patients who received neoadjuvant therapy;
Patients with a survival time of less than 1 month.
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Tianjin Medical University Cancer Institute and Hospital
Address:
City:
Tianjin
Zip:
300060
Country:
China
Status:
Recruiting
Contact:
Last name:
Jihui Hao, Dr
Phone:
+8618622221120
Start date:
May 1, 2023
Completion date:
August 30, 2023
Lead sponsor:
Agency:
Tianjin Medical University Cancer Institute and Hospital
Agency class:
Other
Source:
Tianjin Medical University Cancer Institute and Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05997147
